title: Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
abstract: OBJECTIVE
  To report the safety and efficacy of zotarolimus eluting stents for treatment of unprotected left main coronary artery disease.
  
  
  BACKGROUND
  Percutaneous stent insertion is an increasingly popular alternative to bypass surgery for the management of left main (LM) coronary artery disease. While data support the use of sirolimus- and paclitaxel-coated stents in the LM coronary artery, there are no published series reporting results with Endeavor (zotarolimus) stents, particularly in the context of unprotected left main (ULM) lesions.
  
  
  METHODS
  We retrospectively identified 40 consecutive patients who had ULM disease treated with Endeavor stents (ZES) and who had follow-up angiography. The primary endpoint was the prevalence of major adverse cardiac events (MACE), including cardiac/unexplained death, nonfatal myocardial infarction (MI), and in-stent restenosis (ISR)/target lesion revascularization (TLR).
  
  
  RESULTS
  Angiographic and procedural success was achieved in all cases. Follow-up angiography occurred on average 5.6 ± 0.9 months after the index procedure. There were three incidences of ISR requiring TLR and another patient who had a NSTEMI in the follow-up period. At late follow-up (12.4 ± 1.8 months) three patients underwent CABG (one for RCA stenosis) and four patients died without knowledge of the status of the ULM stent (two cardiovascular and two deaths related to cancer progression).
  
  
  CONCLUSIONS
  In conclusion, our experience with Endeavor stents for the treatment of ULM disease demonstrates excellent angiographic and clinical outcomes, with a 7.5% ISR/TLR rate and a 15% MACE rate, respectively, at an average clinical follow-up of 12.4 months.
authors.affiliation: Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
authors.forename: Trevor
authors.initials: T
authors.lastname: Simard
authors.forename: Benjamin
authors.initials: B
authors.lastname: Hibbert
authors.forename: Aun-Yeong
authors.initials: AY
authors.lastname: Chong
authors.forename: Peter
authors.initials: P
authors.lastname: Ruchin
authors.forename: Michel
authors.initials: M
authors.lastname: Le May
authors.forename: Marino
authors.initials: M
authors.lastname: Labinaz
authors.forename: Michael
authors.initials: M
authors.lastname: Froeschl
authors.forename: Derek
authors.initials: D
authors.lastname: So
authors.forename: Christopher
authors.initials: C
authors.lastname: Glover
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Marquis
authors.forename: Edward
authors.initials: E
authors.lastname: O'Brien
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002423:Cause of Death; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000401:mortality; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D009864:Ontario; D011474:Prosthesis Design; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D020123:Sirolimus